SuperworthNewAmsterdam Pharma price to book ratio NAMS
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 3.7×
- 3-year median
- 4.8×
- Against its 3-year history
- 23rd
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 2.2× to 7.3×
- Peer median
- 3.2×
NewAmsterdam Pharma's price to book ratio is 3.7× as of Oct 23, 2026.
That is below its 3-year median of 4.8×, lower than on 77% of days in the last 3 years.
Over that time it ranged from 2.2× in Apr 2025 to 7.3× in Mar 2024.
The median for 10 large drugmakers of a similar size is 3.2×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 3.7× | 6.8× |
| 2025 | 5.5× | 2.2× | 6.4× |
| 2024 | 6.3× | 3.7× | 7.3× |
Against its peers
Companies in Drug Manufacturers - General nearest NewAmsterdam Pharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| NAMSNewAmsterdam Pharma | 3.7× |
| PBHPrestige Consumer Healthcare | 1.2× |
| HRMYHarmony Biosciences | 2.1× |
| NRIXNurix Therapeutics | 2.9× |
| ANIPANI Pharmaceuticals | 2.8× |
| PAHCPhibro Animal Health | 4.1× |
| OGNOrganon | 3.6× |
| ANABAnaptysbio | 138× |
| LQDALiquidia | 19.6× |
| PCRXPacira BioSciences | 2.2× |
| ARQTArcutis Biotherapeutics | 17.8× |
| Peer median | 3.2× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on NewAmsterdam Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.